Phase II study of Chemotherapy for Advanced or Recurrent Thymoma

UMIN ID: C000000350

Registered date:01/04/2006

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: Thymoma (excluding thymic carcinoma)
• Date of first enrollment: 2006/04/01
• Target sample size: 50
• Countries of recruitment: Japan
• Study type: Interventional
• Intervention(s): Carboplatin AUC5-6, day 1 Paclitaxel 180-210mg/m2 day 1 or 60-70mg/m2 weekly x3

Outcome(s)

• Primary Outcome: Response rate
• Secondary Outcome: Overall response Adverse effects

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: 70years-old
• Gender: Male and Female
• Exclude criteria: Patients with malignancies other than thymoma (those with CR can be included). Patients who has been treated with steroid pulse therapy within one month of the registration. Patients on oral steroid at a dose of more than 26mg every other day or 13mg everyday. Pregnant women.

Related Information

• Primary Sponsor: Japanese Association for Research on the Thymus
• Source(s) of Monetary Support: Japanese Association for Research on the Thymus